Welcome to our dedicated page for Lumos Pharma news (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma stock.
Lumos Pharma, Inc. (formerly NASDAQ: LUMO) has communicated that it is a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, with particular emphasis on Pediatric Growth Hormone Deficiency (PGHD). News about Lumos Pharma has frequently centered on the development of its lead candidate, LUM-201, an oral growth hormone secretagogue, and on key corporate milestones.
Company press releases describe a series of clinical updates from the Phase 2 OraGrowtH210 and OraGrowtH212 trials, where LUM-201 is being evaluated in children with moderate PGHD. These updates have highlighted growth outcomes, biomarker changes in IGF-1 and IGFBP-3, and detailed analyses of pulsatile growth hormone secretion patterns under LUM-201 treatment. Lumos Pharma has also reported presentations of these data at major endocrinology and pediatric endocrine conferences in regions including Europe, Latin America, and the Asia-Pacific.
In addition to clinical data, Lumos Pharma’s news flow has included information about regulatory interactions, such as its End of Phase 2 Meeting with the U.S. Food and Drug Administration regarding a potential placebo-controlled Phase 3 trial of LUM-201 in moderate PGHD. Financial updates, including quarterly results and cash position discussions, have also been part of the company’s public communications during its time as a listed entity.
A significant corporate development reported in the news is the successful completion of a tender offer and merger with Double Point Ventures LLC, after which Lumos Pharma’s common stock ceased trading on NASDAQ and the company began operating as a standalone business of Double Point Ventures. For readers reviewing the LUMO news archive, these items collectively provide historical context on Lumos Pharma’s clinical progress, regulatory discussions, financial reporting, and transition from a public company to a privately held business.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Lumos Pharma, a biopharmaceutical company, announced the presentation of interim data from its OraGrowtH210 and OraGrowtH212 trials at the Pediatric Endocrine Society's annual meeting in May 2023. The oral presentation, led by Dr. Andrew Dauber, focuses on growth response in subjects treated with LUM-201 for idiopathic Pediatric Growth Hormone Deficiency (iPGHD). Additionally, data from the OraGrowtH212 trial will be showcased in a poster presentation by Dr. Fernando Cassorla. LUM-201 represents a potential alternative to painful growth hormone injections, having received Orphan Drug Designation in the US and EU. This progress highlights Lumos Pharma's commitment to developing effective treatments for rare diseases.
Lumos Pharma, Inc. (NASDAQ:LUMO), based in Austin, Texas, announced that it will report its first quarter 2023 financial results after market close on May 3, 2023. The company is advancing its oral therapeutic candidate, LUM-201, for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials. Following the financial results announcement, Lumos will host a conference call and webcast at 4:30 PM ET, inviting investors and the public to participate in the discussion and Q&A session. LUM-201 aims to provide an alternative to traditional growth hormone injections. It has received Orphan Drug Designation in both the U.S. and EU, highlighting its potential impact in treating rare diseases.
AUSTIN, Texas, March 09, 2023 – Lumos Pharma (NASDAQ:LUMO) announced its participation in Oppenheimer’s 33rd Annual Healthcare Conference, taking place virtually from March 13-15, 2023. Lumos Pharma will present on March 14 from 2:00-2:30 PM EDT and will host one-on-one meetings with investors on the same day. The presentation will focus on the company's oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) currently undergoing Phase 2 trials. Lumos Pharma’s lead candidate, LUM-201, has received Orphan Drug Designation in both the US and EU, offering a potential alternative to traditional growth hormone injections.